Navigation Links
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Date:11/7/2011

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a planned interim analysis of a Phase 2b study, SOUND-C2, that showed the combination of two oral direct acting hepatitis C virus (HCV) compounds – the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 with ribavirin (RBV) – was successful in reducing viral load below the lower limit of quantifiable levels at week 12 (viral response) in the majority of treatment-naive patients infected with chronic genotype-1 (GT1) HCV. None of the five study arms included treatment with interferon. These data were presented as a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, CA.

"Results from the planned interim analysis of SOUND-C2 are encouraging," said Stefan Zeuzem, M.D., Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany and lead investigator of the study. "They show that BI 201335 plus BI 207127 with ribavirin suppressed the hepatitis C virus to undetectable levels in the majority of patients in this study. We must now complete the study to confirm if this interferon-free regimen leads to a sustained viral response."

"BI is developing our dual oral direct acting antiviral treatment regimen with the goal of eliminating interferon from HCV treatment. We are excited by these interim results and look forward to final study outcomes," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We also are pleased to present other data from our hepatitis C virus portfolio that underscores our ongoing focus on real-world challenges faced by HCV patients, including traditionally difficult-to-treat populations."

The interferon-free oral combination therapy arms with B
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
2. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
3. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
6. Hepatitis C Phase 2A Trial Positive Results
7. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
10. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral ... Executive Officer, will present live at VirtualInvestorConferences.com on ... 6, 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... live, interactive online event where investors are invited ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... Piper Jaffray Health Care Conference on Wednesday, November 30, ... Palace Hotel in New York. The presentation will be ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: The 2011 Vibrio Diagnostics ... Forecasts by Country http://www.reportlinker.com/p0444741/The-Vibrio-Diagnostics-Market-US-Europe-JapanTest-Volume-and-Sales-Forecasts-by-Country.html ... detailed analysis of the Vibrio diagnostics market in ...
Cached Medicine Technology:The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 2The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 3The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 4
(Date:8/4/2015)... Angeles, CA (PRWEB) , ... August 04, 2015 , ... ... study that found financial incentives to be a viable method for encouraging people to ... wager money on the future of their weight loss success, adding a financial incentive ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... ... 04, 2015 , ... Members receiving care from a doctor who participates in ... that is nine percent lower -- than those members at traditional doctor practices, according ... programs. , “The promise of patient-centered, or value-based, care to deliver better quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are researching online ... physician. In an effort to share more and better information with these savvy ... publicly share patient satisfaction ratings and comments about its doctors and advanced practice ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... you are pregnant, here,s another reason to work out: ... developing neurodegenerative diseases, such as Alzheimer,s, later in life. ... FASEB Journal ( http://www.fasebj.org ) shows that mice ... Alzheimer,s disease showed fewer signs of the disease and ...
... of the leading causes of death and morbidity worldwide, ... 2008, the worldwide cost of cancer due to premature ... to be US$895 billion. An expert report from ... of some of the world,s leading cancer specialists, from ...
... Netherlands: Mothers who are exposed to particular agents during pregnancy ... asthma, according to new research. The study will ... Society,s Annual Congress in Amsterdam. It is ... and chemicals it can cause asthma. However, there has been ...
... The Netherlands: A new study has shown that people ... reduced lung function are at a serious risk of ... presented today (26 September 2011) at the European Respiratory ... COPD and reduced lung function should be routinely screened ...
... and unspoken clues exchanged by patients and doctors exert ... study by the University of Michigan Health System. Researchers ... interviews with participants to help elucidate signals sent and ... The method shows promise for improving medical decision ...
... of personalised medicine, gains in cancer survival over the ... trials with less stringent evidence criteria, a researcher told ... 26 Sept). The introduction of targeted treatments means ... most effective way of getting new treatments to cancer ...
Cached Medicine News:Health News:Pregnant women who exercise protect their offspring against long-term neurodegenerative diseases 2Health News:Unequal access to cancer care can no longer be tolerated 2Health News:Unequal access to cancer care can no longer be tolerated 3Health News:A mother's occupation while pregnant can cause asthma in children 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 3Health News:Smaller, faster trials can improve cancer patient survival 2Health News:Smaller, faster trials can improve cancer patient survival 3
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Sickle Edge blade, straight, 5.0 mm W x 84 mm long. Specially designed for superior visibility and easy access into the ear canal, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: